Xalatan (Latanoprost) Patent Expiration, LOE Window & CMS Spending
Xalatan (Latanoprost) by Viatris: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $5.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Viatris |
| FDA Application & Pathway | N020597 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.1M |
| 2024 Medicare Part D Spend | $4.9M |
| 2024 Medicaid Spend | $168K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 17.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.